PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.
The immediate goals include:
- Regain Current Status with OTC Markets - Open operation in the Dallas, Tx area where the company has relocated - Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe. - Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment. - Further our development in North America of our Flagship HIV immune treatment compound IPF
As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe. The company has made updates to its corporate website, www.enzolytics.com, and will continue to do so to provide further information to our shareholders.
Market Data 
Markets 
AI
